Edition:
India

Curis Inc (CRIS.OQ)

CRIS.OQ on NASDAQ Stock Exchange Global Market

2.45USD
20 Sep 2019
Change (% chg)

$0.19 (+8.41%)
Prev Close
$2.26
Open
$2.26
Day's High
$2.49
Day's Low
$2.26
Volume
131,161
Avg. Vol
34,574
52-wk High
$2.90
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Curis Announces Promotion Of Bill Steinkrauss To Chief Financial Officer
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Curis Inc ::CURIS ANNOUNCES PROMOTION OF BILL STEINKRAUSS TO CHIEF FINANCIAL OFFICER.CURIS INC - STEINKRAUSS JOINED CURIS IN AUGUST 2016 AND MOST RECENTLY SERVED AS TREASURER AND VICE PRESIDENT OF FINANCE.  Full Article

Curis Reports Q1 Loss Per Share $0.30
Wednesday, 15 May 2019 

May 14 (Reuters) - Curis Inc ::CURIS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 REVENUE $1.8 MILLION VERSUS $2.5 MILLION.Q1 LOSS PER SHARE $0.30.  Full Article

Curis Announces Leadership Change
Tuesday, 25 Sep 2018 

Sept 24 (Reuters) - Curis Inc ::CURIS ANNOUNCES LEADERSHIP CHANGE.CURIS INC - COMPANY APPOINTS JAMES DENTZER PRESIDENT AND CEO.CURIS INC - DENTZER WILL BECOME A MEMBER OF CURIS BOARD OF DIRECTORS.CURIS INC - DENTZER REPLACES ALI FATTAEY WHO IS LEAVING COMPANY..  Full Article

Curis Reports Q2 Loss Per Share $0.26
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Curis Inc ::CURIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $2.4 MILLION VERSUS I/B/E/S VIEW $2.3 MILLION.Q2 LOSS PER SHARE $0.26.Q2 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.  Full Article

Curis Announces FDA Fast Track Designation For Fimepinostat (Cudc-907) Development
Thursday, 31 May 2018 

May 31 (Reuters) - Curis Inc ::CURIS ANNOUNCES FDA FAST TRACK DESIGNATION FOR FIMEPINOSTAT (CUDC-907) DEVELOPMENT IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA.  Full Article

Curis Inc says Q3 loss per share $0.11
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Curis Inc -:Curis reports third quarter 2017 financial results.Q3 revenue $2.4 million versus I/B/E/S view $2.2 million.Q3 loss per share $0.11.Q3 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Curis Inc - ‍announce Acceptance Of Investigational New Drug (IND) application for CA-4948​.  Full Article